Luo Jun, Ling Zhiqiang, Mao Weimin
Zhejiang Cancer Hospital, Zhejiang Cancer Research Institute, Hangzhou 310022, China.
Zhongguo Fei Ai Za Zhi. 2011 Aug;14(8):669-73. doi: 10.3779/j.issn.1009-3419.2011.08.06.
Lung cancer is one of the most common malignancies. The aim of this study is to investigate the relationship between the change of lymphocyte subsets in the peripheral blood of lung cancer patients and the survival rate.
Flow cytometry was used to measure the percentages of lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8+, CD19+, CD25+, CD44+, and NK cells) in peripheral blood obtained from 221 patients with primary lung cancer without any treatment and from 96 healthy blood donors as the control group. The result was combined with clinical and follow-up data and statistical analysis was conducted.
The levels of CD3+ and CD8+ in the patient group are significantly lower compared with the control group, whereas the levels of CD4+/CD8+, CD19+, CD25+, CD44+, and NK cells are significantly higher (P<0.05). CD8+ is significantly higher in the small cell lung cancer (SCLC) group compared with the non-small cell lung cancer (NSCLC) group. However, CD4+ and CD4+/CD8+ are lower in SCLC (P<0.05). There were no significant differences in different stages and differentiation (P>0.05) in the NSCLC group. The level of CD3+ was significantly higher compared with the pre-chemotherapy group, but NK cell, CD19+, and CD44+ were distinctly lower in the post-chemotherapy group (P<0.05). More survival opportunities will be obtained for patients with no increase in CD44+ after chemotherapy (P=0.021), but the other three indices have no obvious influence on survival.
Widespread changes of lymphocyte occur in the peripheral blood of patients with lung cancer. There is a significant correlation between the change of CD44+ and the prognosis after chemotherapy.
肺癌是最常见的恶性肿瘤之一。本研究旨在探讨肺癌患者外周血淋巴细胞亚群变化与生存率之间的关系。
采用流式细胞术检测221例未经任何治疗的原发性肺癌患者及96例健康献血者（作为对照组）外周血中淋巴细胞亚群（CD3+、CD4+、CD8+、CD4+/CD8+、CD19+、CD25+、CD44+和NK细胞）的百分比。将结果与临床及随访数据相结合并进行统计分析。
患者组CD3+和CD8+水平显著低于对照组，而CD4+/CD8+、CD19+、CD25+、CD44+和NK细胞水平显著高于对照组（P<0.05）。小细胞肺癌（SCLC）组CD8+水平显著高于非小细胞肺癌（NSCLC）组。然而，SCLC组CD4+和CD4+/CD8+水平较低（P<0.05）。NSCLC组不同分期和分化程度之间无显著差异（P>0.05）。化疗后组CD3+水平显著高于化疗前组，但化疗后组NK细胞、CD19+和CD44+水平明显较低（P<0.05）。化疗后CD44+未升高的患者将获得更多生存机会（P=0.021），但其他三项指标对生存无明显影响。
肺癌患者外周血淋巴细胞发生广泛变化。CD44+变化与化疗后预后显著相关。
